Beijing, China

Amar Kureishi

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Aicuris Gmbh + Co. Kg.. Active years: 2013.



Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Amar Kureishi

Introduction

Amar Kureishi is a notable inventor based in Beijing, China. He has made significant contributions to the field of antiviral treatments, particularly in relation to HIV infections and AIDS. His work focuses on the development of novel therapeutic approaches that combine various antiviral agents.

Latest Patents

Kureishi holds a patent for his invention titled "Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases." This patent relates to the use of parapoxviruses in conjunction with other agents for treating viral diseases, specifically targeting HIV infections and AIDS. The invention also encompasses methods for producing medicaments based on these combinations, which are crucial for antiretroviral therapy and highly active antiretroviral therapy (HAART). He has 1 patent to his name.

Career Highlights

Amar Kureishi is associated with Aicuris GmbH & Co. KG, a company dedicated to developing innovative antiviral therapies. His work at Aicuris has positioned him as a key player in the fight against viral diseases, contributing to advancements in medical treatments.

Collaborations

Kureishi collaborates with esteemed colleagues such as Daniela Paulsen and Helga Ruebsamen-Schaeff. Their combined expertise enhances the research and development efforts at Aicuris, fostering an environment of innovation.

Conclusion

Amar Kureishi's contributions to antiviral research and his innovative patent highlight his commitment to improving treatment options for viral diseases. His work continues to inspire advancements in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…